Cold Spring Harbor Laboratory (CSHL) is ranked #1 on Innovation Impact’s Productivity Score among Pure Research/Health Care Institutions, as well as #1 for Patent Citations by the George W. Bush Presidential Center.
In their yearly report, “The Innovation Impact of U.S. Universities,” the Bush Center measures the innovations of American research institutions and highlights works from the top performers. CSHL was chosen as an institution that “illustrates the social benefits from cutting-edge research” through its basic research. The report highlights SPINRAZA®, the novel antisense oligonucleotide approved by the FDA for treating spinal muscular atrophy. It was developed by CSHL Professor Adrian Krainer.